Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) retained Canaccord Genuity Group Inc. (TSX:CF) to assist in this effort as part of an evaluation of strategic and financial alternatives. Titan and Braeburn Pharmaceuticals (BBRX) are in discussions regarding their partnership for the development and commercialization of Probuphine.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.67 USD | +9.04% |
|
+19.12% | -31.27% |
02/07 | Top Premarket Gainers | MT |
15/05 | Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-31.27% | 4.75M | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B |
- Stock Market
- Equities
- TTNP Stock
- News Titan Pharmaceuticals, Inc.
- Titan Retains Canaccord Genuity To Assist In Strategic And Financial Alternatives